The invention relates to a liver microtissue, preferably a liver microtissue comprising at least 3 different phenotypes of liver cells obtained from induced pluripotent stem cells encapsulated in a single three-dimensional closed microcompartment. The invention also relates to a method for preparing the liver microtissue and its uses in treatment or prevention of liver failure.

The invention relates generally to cell-derived vesicles (CDVs), such as CD Vs from myoblast, wherein the parent cells have been subjected to pulsed electromagnetic field and wherein the vesicles are isolated from the parent cells using actin cytoskeletal disruptors, such as cytochalasin B. The CDVs are enriched for Transient Receptor Potential Channel 1 (TRPC1). The invention further relates to the uses of the CDVs as therapeutic agents in conditions associated with disruptive metabolism and inflammation; for instance, cancer.

Hypoimmunogenic cell lines and methods and compositions for their production are provided.

The present invention provides methods for isolating and cryopreserving tumor infiltrating lymphocytes (TILs) and producing therapeutic populations of TILs, including methods via use of a kit and a semi-automatic device for aseptic disaggregation, enrichment, and cryopreservation of a resected tumor prior to expansion of the TIL population. The present invention also provides methods for expansion, and/or stabilization of TILs, for instance UTILs, compositions involving the same and methods of treatment involving the same.

The present invention provides methods for isolating and cryopreserving tumor infiltrating lymphocytes (TILs) and producing therapeutic populations of TILs, including methods via use of a kit and a semi-automatic device for aseptic disaggregation, enrichment, and cryopreservation of a resected tumor prior to expansion of the TIL population. The present invention also provides methods for expansion, and/or stabilization of TILs, for instance UTILs, compositions involving the same and methods of treatment involving the same.

A bioactive suspension derived from freshly disaggregated tissue is provided, as well as related methods of formulation and use. The bioactive suspension may comprise a cell-free supernate derived from epidermal and dermal tissue that has been enzymatically and mechanically disaggregated, then separated, and which may contain tissue regeneration factors known to speed healing. The bioactive suspension may further comprise genetically-modified treatment cells, wild type cells, or both, and may be combined with one or more scaffolding elements to form a bioactive suspension combination product suitable for treatment of a cutaneous defect. Synthetic bioactive suspensions and bioactive suspension combination products are also provided.

A bioactive suspension derived from freshly disaggregated tissue is provided, as well as related methods of formulation and use. The bioactive suspension may comprise a cell-free supernate derived from epidermal and dermal tissue that has been enzymatically and mechanically disaggregated, then separated, and which may contain tissue regeneration factors known to speed healing. The bioactive suspension may further comprise genetically-modified treatment cells, wild type cells, or both, and may be combined with one or more scaffolding elements to form a bioactive suspension combination product suitable for treatment of a cutaneous defect. Synthetic bioactive suspensions and bioactive suspension combination products are also provided.

The present invention relates to the use of warmers, or autonomous heat packs, for heating and maintaining a solution at a suitable temperature, for the period of time required to accomplish a chemical, biochemical or biological reaction, in particular in molecular biology or cell biology applications. Biology kits containing warmers are also part of this invention.

The present invention relates to a composition for disrupting tissue material, the composition comprising solid disrupting particles in combination with at least one enzyme for enzymatic lysis and at least one chaotropic agent, as well as to a method for disrupting tissues material by simultaneously applying mechanical grinding or milling disruption and enzymatic digestion.

The invention relates to a process for the manufacture of a population of human allogeneic liver-derived progenitor cells (HALPC), comprising the use of microcarriers and a bioreactor.